Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Cash & Equivalents (2016 - 2025)

Sunshine Biopharma's Cash & Equivalents history spans 14 years, with the latest figure at $9.1 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 5.81% year-over-year to $9.1 million; the TTM value through Dec 2025 reached $9.1 million, down 5.81%, while the annual FY2025 figure was $9.1 million, 5.81% down from the prior year.
  • Cash & Equivalents reached $9.1 million in Q4 2025 per SBFM's latest filing, down from $9.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $41.7 million in Q2 2022 to a low of $1.7 million in Q2 2021.
  • Average Cash & Equivalents over 5 years is $14.4 million, with a median of $11.9 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 16522.83% in 2021, then crashed 53.53% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $2.0 million in 2021, then skyrocketed by 967.22% to $21.8 million in 2022, then fell by 25.35% to $16.3 million in 2023, then plummeted by 40.55% to $9.7 million in 2024, then dropped by 5.81% to $9.1 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Cash & Equivalents are $9.1 million (Q4 2025), $9.3 million (Q3 2025), and $10.3 million (Q2 2025).